FDA Letter API

Thrive Health and Wellness, LLC dba Thrive Health Solutions

Letter data

Company
Thrive Health and Wellness, LLC dba Thrive Health Solutions
Recipient
Doug Hatch | Owner | Thrive Health and Wellness, LLC dba Thrive Health Solutions | 88 Inverness Circle East, Ste A-204 | Englewood | , | CO | 80112-5521 | United States
Issue date
2026-07-27
Posted date
Not available
FDA office
Center for Drug Evaluation and Research (CDER)
Subject
Not available
Product
Drugs
CMS ID
714891
Reference number
Not available
FEI
Not available
Inspection dates
Not available

Normalized citations

21 CFR: None found

21 U.S.C.: None found

Related FDA links

No related FDA letter link is present in the source index.

Full source text

CLOSEOUT LETTER Thrive Health and Wellness, LLC dba Thrive Health Solutions MARCS-CMS 714891 — July 27, 2026 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: Via Electronic Mail - Delivery and Read Receipt Requested Product: Drugs Recipient: Recipient Name Doug Hatch Recipient Title Owner Thrive Health and Wellness, LLC dba Thrive Health Solutions 88 Inverness Circle East, Ste A-204 Englewood , CO 80112-5521 United States Issuing Office: Center for Drug Evaluation and Research (CDER) United States Secondary Issuing Offices United States Dear Mr. Hatch: The U.S. Food and Drug Administration (FDA) has completed an evaluation of your firm’s corrective actions in response to our warning letter #714891, issued on February 9, 2026. Based on our evaluation, it appears that you have adequately addressed the violations contained in this warning letter. You are expected to take all necessary steps to ensure compliance with the Federal Food, Drug, and Cosmetic Act and FDA’s implementing regulations. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means. Sincerely, /S/ Matthew J. Lash Acting Director Office of Compounding Quality and Compliance Office of Compliance Center for Drug Evaluation and Research Content current as of: 08/06/2026 Regulated Product(s) Drugs